Phenol neurolysis for relieving intermittent involuntary painful spasm in upper motor neuron syndromes: a pilot study.
DOI:
https://doi.org/10.2340/16501977-0310Keywords:
spasticity, neurolysis, rehabilitation, pain management.Abstract
OBJECTIVE: The aim of this study was to assess the efficacy of phenol neurolysis in relieving intermittent attacks of involuntary painful muscle spasm in patients with upper motor neurone syndromes. DESIGN: Case series. PATIENTS: Nineteen patients with intermittent involuntary painful muscle spasm of one of the following muscles: extensor hallucis longus (n=13), psoas major (n=3), tensor fascia lata (n=1) or vastus lateralis (n=2). METHODS: Phenol neurolysis was performed for the target muscles using a Teflon-coated stainless-steel injection needle (connected to a block stimulator). The change in frequency and severity of intermittent involuntary painful muscle spasm was assessed 1, 2, 8 and 24 weeks after neurolysis. RESULTS: The frequency and severity of intermittent involuntary painful muscle spasm decreased in all patients for 24 weeks following neurolysis. Analgesic drugs were not required for the intermittent involuntary painful muscle spasm and no serious side-effects were observed following neurolysis. CONCLUSION: Phenol neurolysis gave promising results in treating intermittent involuntary painful muscle spasm in patients with upper motor neurone syndromes.Downloads
Downloads
Published
How to Cite
Issue
Section
License
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
